AEON Biopharma, Inc.
AEON
$0.466
-$0.0655-12.32%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.63M | 3.04M | 3.32M | 4.65M | 4.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.67M | 4.02M | 7.76M | 10.38M | 11.54M |
| Operating Income | -5.67M | -4.02M | -7.76M | -10.38M | -11.54M |
| Income Before Tax | 2.08M | -6.17M | 164.11M | -118.02M | -26.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.08M | -6.17M | 164.11M | -118.02M | -26.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.08M | -6.17M | 164.11M | -118.02M | -26.24M |
| EBIT | -5.67M | -4.02M | -7.76M | -10.38M | -11.54M |
| EBITDA | -5.64M | -3.99M | -7.74M | -10.36M | -11.52M |
| EPS Basic | 3.76 | -11.24 | 304.20 | -228.00 | -50.85 |
| Normalized Basic EPS | -5.35 | -4.89 | 1.26 | -65.40 | -3.70 |
| EPS Diluted | 3.47 | -11.52 | 304.20 | -228.00 | -50.85 |
| Normalized Diluted EPS | -5.34 | -4.89 | 1.26 | -65.40 | -3.70 |
| Average Basic Shares Outstanding | 554.30K | 548.80K | 539.50K | 517.60K | 516.10K |
| Average Diluted Shares Outstanding | 555.30K | 548.80K | 539.50K | 517.60K | 516.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
